Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
105 hedge funds and large institutions have $138M invested in Accelerate Diagnostics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 34 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
11% more funds holding
Funds holding: 95 → 105 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
18% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 34
29% less capital invested
Capital invested by funds: $195M → $138M (-$56.5M)
79% less call options, than puts
Call options by funds: $270K | Put options by funds: $1.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
+$3.03M |
| 2 |
Millennium Management
New York
|
+$1.17M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$708K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$624K |
| 5 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$469K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Chicago Capital
Chicago,
Illinois
|
-$6.01M |
| 2 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$1.1M |
| 3 |
GAM
Griffin Asset Management
New York
|
-$999K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$974K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$709K |
AXDX Hedge Fund Activity: Q3 2021 in Review
105 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2021, worth a combined $138M — down 29% from $195M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AXDX positions and 5 closed out — a net gain of 11 holders — while 28 added to existing stakes and 34 trimmed.
The largest buyer was PenderFund Capital Management, opening a new position worth an estimated $3.03M. The largest seller was Chicago Capital, cutting an estimated $6.01M.
- 105 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2021, up from 95 in Q2 2021.
- Funds reported $138M of Accelerate Diagnostics stock for Q3 2021, down 29% quarter-over-quarter.
- 16 funds opened new Accelerate Diagnostics positions in Q3 2021 and 5 closed out, a net change of +11 holders.
- The largest Accelerate Diagnostics buyer in Q3 2021 was PenderFund Capital Management, an estimated $3.03M added.
- The largest Accelerate Diagnostics seller in Q3 2021 was Chicago Capital, an estimated $6.01M sold.
Based on aggregated 13F filings for Q3 2021.